We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Neuro Therapia Stock

Invest in or calculate the value of your shares in Neuro Therapia or other pre-IPO companies through EquityZen's platform.

Get Started

Neuro Therapia Stock (NERT)

Neuro Therapia is developing new therapies for diseases with an underlying component of neuroinflammation.

About Neuro Therapia Stock

Founded

2015

Headquarters

Ohio, IL, US

Industries

Software, Artificial Intelligence, Data and Analytics

NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain. Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016.

Neuro Therapia Management

Leadership team at Neuro Therapia

Founder

Mohamed Naguib

President & CEO

Tony Giordano

Locked Features

Join now and verify your accreditation status to gain access to:

  • Neuro Therapia current valuation
  • Neuro Therapia stock price
  • Available deals in Neuro Therapia and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Neuro Therapia stock?

Accredited investors can buy pre-IPO stock in companies like Neuro Therapia through EquityZen funds. These investments are made available by existing Neuro Therapia shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Neuro Therapia stock?

Shareholders can sell their Neuro Therapia stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."